tetano
Editor, Senior Moderator
SLAS Discov
. 2024 Aug 20:100180.
doi: 10.1016/j.slasd.2024.100180. Online ahead of print. High Throughput Screening for SARS-CoV-2 Helicase Inhibitors
Yuka Otsuka[SUP] 1 [/SUP], Eunjung Kim[SUP] 2 [/SUP], Austin Krueger[SUP] 2 [/SUP], Justin Shumate[SUP] 1 [/SUP], Chao Wang[SUP] 2 [/SUP], Bilel Bdiri[SUP] 2 [/SUP], Sultan Ullah[SUP] 2 [/SUP], HaJeung Park[SUP] 2 [/SUP], Louis Scampavia[SUP] 1 [/SUP], Thomas D Bannister[SUP] 2 [/SUP], Donghoon Chung[SUP] 3 [/SUP], Timothy P Spicer[SUP] 4 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for nearly 7 million deaths worldwide since its outbreak in late 2019. Even with the rapid development and production of vaccines and intensive research, there is still a huge need for specific anti-viral drugs that address the rapidly arising new variants. To address this concern, the National Institute of Allergy and Infectious Diseases (NIAID) established nine Antiviral Drug Discovery (AViDD) Centers, tasked with exploring approaches to target pathogens with pandemic potential, including SARS-CoV-2. In this study, we sought inhibitors of SARS-CoV2 non-structural protein 13 (nsP13) as potential antivirals, first developing a HTS-compatible assay to measure SARS-CoV2 nsP13 helicase activity. Here we present our effort in implementing the assay in a 1,536 well-plate format and in identifying nsP13 inhibitor hit compounds from a ∼650,000 compound library. The primary screen was robust (average Z' = 0.86 ± 0.05) and resulted in 7,009 primary hits. 1,763 of these compounds upon repeated retests were further confirmed, showing consistent inhibition. Following in-silico analysis, an additional orthogonal assay and titration assays, we identified 674 compounds with IC[SUB]50[/SUB] <10 μM. We confirmed activity of independent compound batches from de novo powders while also incorporating multiple counterscreen assays. Our study highlights the potential of this assay for use on HTS platforms to discover novel compounds inhibiting SARS-CoV2 nsP13, which merit further development as an effective SARS-CoV2 antiviral.
Keywords: Biochemical assay; COVID-19; HTS; Helicase; nsP13.
. 2024 Aug 20:100180.
doi: 10.1016/j.slasd.2024.100180. Online ahead of print. High Throughput Screening for SARS-CoV-2 Helicase Inhibitors
Yuka Otsuka[SUP] 1 [/SUP], Eunjung Kim[SUP] 2 [/SUP], Austin Krueger[SUP] 2 [/SUP], Justin Shumate[SUP] 1 [/SUP], Chao Wang[SUP] 2 [/SUP], Bilel Bdiri[SUP] 2 [/SUP], Sultan Ullah[SUP] 2 [/SUP], HaJeung Park[SUP] 2 [/SUP], Louis Scampavia[SUP] 1 [/SUP], Thomas D Bannister[SUP] 2 [/SUP], Donghoon Chung[SUP] 3 [/SUP], Timothy P Spicer[SUP] 4 [/SUP]
Affiliations
- PMID: 39173831
- DOI: 10.1016/j.slasd.2024.100180
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for nearly 7 million deaths worldwide since its outbreak in late 2019. Even with the rapid development and production of vaccines and intensive research, there is still a huge need for specific anti-viral drugs that address the rapidly arising new variants. To address this concern, the National Institute of Allergy and Infectious Diseases (NIAID) established nine Antiviral Drug Discovery (AViDD) Centers, tasked with exploring approaches to target pathogens with pandemic potential, including SARS-CoV-2. In this study, we sought inhibitors of SARS-CoV2 non-structural protein 13 (nsP13) as potential antivirals, first developing a HTS-compatible assay to measure SARS-CoV2 nsP13 helicase activity. Here we present our effort in implementing the assay in a 1,536 well-plate format and in identifying nsP13 inhibitor hit compounds from a ∼650,000 compound library. The primary screen was robust (average Z' = 0.86 ± 0.05) and resulted in 7,009 primary hits. 1,763 of these compounds upon repeated retests were further confirmed, showing consistent inhibition. Following in-silico analysis, an additional orthogonal assay and titration assays, we identified 674 compounds with IC[SUB]50[/SUB] <10 μM. We confirmed activity of independent compound batches from de novo powders while also incorporating multiple counterscreen assays. Our study highlights the potential of this assay for use on HTS platforms to discover novel compounds inhibiting SARS-CoV2 nsP13, which merit further development as an effective SARS-CoV2 antiviral.
Keywords: Biochemical assay; COVID-19; HTS; Helicase; nsP13.